Skip navigation
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLev, Baruch-
dc.contributor.authorSarath, Bharat-
dc.contributor.authorSougiannis, Theodore-
dc.date.accessioned2008-06-04T16:01:29Z-
dc.date.available2008-06-04T16:01:29Z-
dc.date.issued2004-06-
dc.identifier.urihttp://hdl.handle.net/2451/27470-
dc.description.abstractThe immediate expensing of R&D expenditures is often justified by the conservatism principle. However, no accounting procedure consistently applied can be conservative throughout the firm' life. We ask the following questions: (a) When is the expensing of R&D conservative and when is it aggressive, relative to R&D capitalization? and (b) What are the capital market implications of these reporting biases? To address these questions we construct a model of profitability biases (differences between reported profitability under R&D expensing and capitalization) and show that the key drivers of the reporting biases are the differences between R&D growth and earnings growth (momentum), and between R&D growth and return on equity (ROE). Companies with a high R&D growth rate relative to their profitability (typically early cycle companies) report conservatively, while firms with a low R&D growth rate (mature companies) tend to report aggressively under current GAAP. Our empirical analysis, covering the period 1972-2003, generally supports the analytical predictions. In the valuation analysis we find evidence consistent with investor fixation on the reported profitability measures: we detect undervaluation of conservatively reporting firms and overvaluation of aggressively reporting firms. These misvaluations appear to be corrected when the reporting biases reverse from conservative to aggressive and vice versa.en
dc.language.isoen_USen
dc.relation.ispartofseriesBaruch Lev-10en
dc.titleR&D Reporting Biases and their Consequencesen
dc.typeWorking Paperen
Appears in Collections:Accounting Working Papers

Files in This Item:
File Description SizeFormat 
SSRN-id561602.pdf412 kBAdobe PDFView/Open


Items in FDA are protected by copyright, with all rights reserved, unless otherwise indicated.